For the first time in 105 years, medicine has something to offer type 1 diabetes patients beyond insulin. The UK's National Institute for Health and Care Excellence (Nice) has approved teplizumab (Tzield, made by Sanofi) for use on the NHS in England and Wales — the world's first drug that can delay the onset of type 1 diabetes by up to three years. The immunotherapy doesn't cure the disease, but it buys time: precious years free from finger-pricks, insulin...